PIRIDRONIC ACID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C7H11NO6P2
Molecular Weight	267.1129
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OP(O)(=O)C(CC1=NC=CC=C1)P(O)(O)=O

InChI

InChIKey=NGMZSXZBZNXBGX-UHFFFAOYSA-N

InChI=1S/C7H11NO6P2/c9-15(10,11)7(16(12,13)14)5-6-3-1-2-4-8-6/h1-4,7H,5H2,(H2,9,10,11)(H2,12,13,14)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9052507 | https://www.ncbi.nlm.nih.gov/pubmed/18327899 | https://apps.who.int/iris/bitstream/handle/10665/275696/WHO-EMP-RHT-TSN-2013.1-eng.pdf | Elks, J. (2014) The Dictionary of Drugs: Chemical Data, page 995, retrieved from: https://books.google.ru/books?id=0vXTBwAAQBAJ

Piridronic acid is pyridinyl bisphosphonate. It is the bone calcium metabolism regulator. Piridronic acid was used for the treatment of osteoporosis. It is the human farnesyl pyrophosphate synthase inhibitor. When expressed on an actual or anticipated clinical dose basis for osteoporosis piridronic acid may have a greater potential for inducing gastric damage than do pyridinyl bisphosphonates. Piridronic acid induced significantly more antral damage than risedronate and a greater number of lesions compared to pamidronate and risedronate.

Approval Year

PubMed

Title	Date	PubMed
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.	2008-04-10	18327899
Nonclinical model for assessing gastric effects of bisphosphonates.	1997-02	9052507

Name

Type

Language

piridronic acid [INN]

Preferred Name

English

PIRIDRONIC ACID

Official Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2136